Omar Sherief Mohammad Appointed Head India, Middle East & Africa – Roche Diabetes Care!
– Will lead Roche in designing a patient-centric approach to address the diabetes burden in the IMEA region
Chennai, 1st June 2021: Roche announced the appointment of Omar Sherief Mohammad as Head India, Middle East & Africa (IMEA) within the Roche Diabetes Care (RDC) Global Commercial Organisation, based in Mumbai. Prior to this appointment, Omar has been General Manager RDC India since September 2019.
In this new capacity, Omar will play a key role in the shaping and executing of the overall commercial Go-To-Market Strategy, responsible for setting the strategic direction for IMEA, in alignment with the Global Commercial Organisation as well as the overall RDC strategy. In this newly created role, Omar will have direct oversight of IMEA and the RDC General Managers/Country Heads of these markets will directly report to him. Omar will also be General Manager in India.
Speaking about the new appointment, Omar said, “I strongly feel that there is a need for improving access to care in order to support the underprivileged section of the community by creating a holistic ecosystem for screening, awareness and education programs. I look forward to leading my teams across the IMEA region towards dedicating efforts to bend the curve of diabetes in terms of prevalence and adding value by bringing true relief for people with diabetes.”
As GM India, Omar implemented a strategic patient-centric approach towards improving access to care. Under his leadership, RDC India pioneered the adoption of a Figital approach to enhance education and awareness about latest tech-enabled solutions to improve patient care. During his tenure, the company forged meaningful partnerships with like-minded public and private players to create a comprehensive eco-system of care to support underprivileged sections of the community. On the occasion of World Diabetes Day 2020, RDC India partnered with the Maharashtra state government to donate blood glucose monitoring devices to underprivileged people in rural Maharashtra. To further support the government in this time of covid-19 crisis, last year RDC India donated money to the PM relief fund and PPE kits to BMC hospitals in Mumbai.
As head of IMEA, Omar will steer the countries under his charge to amplify this patient-centric approach and collaborate with various stakeholders to address the burden of diabetes in the region.
Omar has two decades of experience in pharmaceutical sector, primarily in diabetes care, in India, global marketing in Denmark and emerging Asian markets. Prior to joining Roche, Omar was the VP and GM of Novo Nordisk, Vietnam and other Southeast Asia emerging markets.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualise relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr one of the most popular diabetes management apps is part of Roche Diabetes Care.
For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
